

In silico interaction of hesperidin with some immunomodulatory targets: A docking analysis

Aditya Ganeshpurkar^{1, 2} & Ajay Saluja^{1, 3*}

¹Faculty of Pharmacy, Gujarat Technological University, Ahmedabad -382 424, Gujarat, India

²Shri Ram Institute of Technology- Pharmacy, Jabalpur -482 002, Madhya Pradesh, India

³AR College of Pharmacy, Vallabh Vidyanagar -388 120, Gujarat, India

Received 16 May 2018; revised 15 September 2018

Forms eternal era, plant, mineral and animal products are used as drugs for the treatment of various diseases. The use of medicinal plants for immunomodulation has a long history. The modern medicinal compounds find their leads in natural products. Immunomodulation amends the immune system of an individual by prying with its usual functions. Discovery of immunomodulators from natural sources has been comprehensively made to modulate the immune system to prevent diseases. Hesperidin has been investigated for its potential anti-inflammatory effects. Hesperidin demonstrated analgesic effects in experimental animals. The present study is focused on exploring the *in silico* interaction of hesperidin with some chemokines and inflammatory targets. In this study, hesperidin was docked with TNF- α , IL-1 β , IL-6, and NOs. Docking studies revealed the excellent interaction of hesperidin with these targets. The result of this work provided an insight into the discovery of novel molecules for immunomodulation and treatment of inflammatory disorders. Additional studies on hesperidin and associated flavonoids are necessary to establish its safety. Hesperidin, can, therefore, can be considered as a candidate for development of an immunomodulatory agent.

Keywords: Cytokines, Hesperidin, Immunomodulatory, Inflammation, Nitric oxide

The immune system is a comprehensive network that defends the body against invading pathogens. A breakdown in the functioning of the immune system makes it react in an inappropriate manner¹. The damage to immune system poses a biological burden on the body by altering the immunological profile (due to allergy or autoimmunity)². Thus, it seems necessary to modulate the immune system during the event of immunosuppression or immunostimulation. Both these classes of synthetic drugs (*i.e.* immunostimulants and immunosuppressants) act by redefining the functions of immune cells either by suppressing or stimulating their activities³. However, these drugs have long-term adverse effects like persistent immunosuppression, general weakness, alopecia, *etc.*

The phenomenon that immune responses are modulated to alleviate diseases has existed in many forms of traditional medicine beliefs, with plants being used in such systems to promote health and to maintain the body's resistance against infections by potentiating immunity⁴. Some of these plants are specifically

stimulatory or suppressive, and normalize or modulate pathophysiological processes, and are thereby termed 'immunomodulatory'^{5,6}.

Flavonoids are one of the important phytoconstituents having varied biological effects on living systems. Owing to their antioxidant effects, flavonoids are acknowledged for hepatoprotective, nephroprotective and cardio-protective effects^{7,8}. Flavonoids also interfere with the functioning of pro-inflammatory cytokines and chemokines. Hesperidin is citrus flavonoids^{9,10}. It is acknowledged for prevention of capillary fragility. Hesperidin administration (orally) in rats significantly allayed irradiation-induced inflammation¹¹. The modification of lymphocyte composition in the intestinal epithelium was observed due hesperidin¹². Hesperidin treatment in mice significantly suppressed levels of TNF- α ¹³, IL-1 β and IL-6¹⁴ in mice. There was a decrease in the expression of NOs¹⁵. Based on the above evidence, the present study aims to explore *in silico* interaction of hesperidin with interleukins, TNF- α , and NOs.

Materials and methods

Software

Python 2.7-language was downloaded from www.python.com¹⁶. Molecular graphics laboratory (MGL) tools and AutoDock 4.2¹⁷ was downloaded

*Correspondence:

Phone: +91-2692-230788 (Mob)

E-mail: akspharmacy@yahoo.com

from www.scripps.edu, Discovery Studio visualizer 4.1¹⁸ was downloaded from www.accelerys.com. Calculations were performed on Windows 8.0 Operating System.

Protein preparation

The three-dimensional crystalline structures of 4 targeted proteins were retrieved from the Protein Data Bank (<http://www.rcsb.org/>). The retrieved protein was TNF- α (PDB ID: 2AZ5), IL-1 β (PDB ID: 2NVH), IL-6 (PDB ID: 1P9M) and NOs (PDB ID: 1NSI). The coordinates of the structures were complexed with water molecules, and other atoms which are responsible for increased resolution and therefore the water molecules and het-atoms were removed using discovery studios and saved in .pdb format.

Docking analysis

Docking studies were performed to analyze interactions of hesperidin with immunomodulatory targets¹⁹. The three-dimensional crystalline structures of 4 proteins were obtained from Protein Data Bank (<http://www.rcsb.org/>). These protein were TNF- α (PDB ID: 2AZ5), IL 1 β (PDB ID: 2NVH), IL-6 (PDB ID: 1P9M) and NOs (PDB ID: 5UO1). The structurally refined protein .pdb files were converted to .pdbqt files using grid module of autodock tools 1.5.6. Charges were assigned to the ions to the proteins manually wherever necessary. The 2D and 3D chemical structures of hesperidin (Molecular formula: C₂₈H₃₄O₁₅; Molecular weight 610.57 g/mol) was retrieved

(<http://pubchem.ncbi.nlm.nih.gov/>). These .sdf and .mol files obtained from PubChem were converted into .pdb files using Marvin Sketch (<http://www.chemaxon.com/marvin/sketch/index.jsp>). These .pdb files were converted to .pdbqt using ligand preparation module of autodock tools 1.5.6. The docking analysis of hesperidin was carried out using the Autodock tools (ADT) v1.5.4 and autodock v 4.2 programs. Hesperidin was docked to all the target protein complexes with the molecule considered as a rigid body. The search was carried out with the Lamarckian Genetic Algorithm; populations of 100 individuals with a mutation rate of 0.02 have been evolved for ten generations. The remaining parameters were set as default. The Docked structure was then visualised using Discovery Studio 2016 for obtaining the binding interactions.

Results

The four crystal structures of proteins were retrieved from protein databank. A docking was performed to identify the precise binding sites on various immunomodulatory targets. Molecular docking is an effective approach that helps to envisage the principal ‘binding modes’ of the ligand with the ‘protein/receptor/enzyme’ having known ‘three-dimensional structure’.

In the present study, docking was carried out on active sites of four target proteins 2AZ5, 1ITB, 1P9M and 5UO1 with hesperidin. Docking interactions of these targets with hesperidin are presented in (Figs. 1-4).




Fig. 1 — Molecular docking studies of hesperidin against TNF- α . (A) 2D-interactions & (B) 3D-interactions




Fig. 2 — Molecular docking studies of hesperidin against IL-1 β . A - 2D-interactions, B - 3D-interactions




Fig. 3 — Molecular docking studies of hesperidin against IL-6. (A) 2D-interactions & (B) 3D-interactions

The binding energy of hesperidin for TNF- α was -6.96 kcal/mol, IL-1 β -6.64 kcal/mol, IL-6 -7.07 kcal/mol, and for NOs -6.83 kcal/mol. Multiple interactions were observed with the binding of hesperidin to TNF- α . Serine 69 (1.36 Å), leucine 120 (1.46 Å) and Tyrosine 151 (1.34 Å) from B chain of TNF- α interacted with glycone part of hesperidin via hydrogen bonding. π -alkyl interaction at Tyrosine 119 (A chain) (1.39 Å) and π - π interaction at Tyrosine 119 (B chain) (1.37 Å) were observed. In case of IL-1 β , glutamic acid 37 (1.45 Å), 64 (1.21 Å) and lysine 65 (1.55 Å) from (A chain) demonstrated hydrogen binding. Methionine 20

(A chain) (1.52 Å) revealed π -sulphur interaction and proline 23 (A chain) (1.52 Å) showed π -alkyl interaction. Hesperidin interacted with IL-6 in multiple ways. Hydrogen binding at methionine 67 (1.45 Å), glutamic acid 172 (1.49 Å), serine 176 (1.23 Å) and arginine 179 (B chain) (1.53 Å) was seen. At arginine 179 (B chain) (1.57 Å) π -alkyl interaction with hesperidin aglycone was observed. An unfavorable donor-donor interaction at alanine 180 (B chain) (1.46 Å) was seen. With respect to NOS, hydrogen bonding, π -sigma interaction, π -alkyl interaction, carbon-hydrogen bond, and vander Waal interaction




Fig. 4 — Molecular docking studies of hesperidin against NOs. (A) 2D-interactions & (B) 3D-interactions

were observed. Hydrogen bonding was seen at aspartic acid 476 (1.07 Å) and glutamic acid 710 (A chain) (1.23 Å). van der Waal interaction was seen at glutamine 712 (A chain) (1.52 Å). Carbon -hydrogen binding was observed at arginine 470 (1.48 Å) and glycine 473 (A chain) (1.49 Å). π -sigma interaction was observed at tyrosine 711 (1.13 Å) whereas π -alkyl interaction was seen at proline 713 (A chain) (1.59 Å).

Discussion

Macrophages play a key function in the production of inflammatory cytokines and chemokines (e.g. TNF- α and pro-inflammatory interleukins). TNF- α , early recognized as an endotoxin-induced glycoprotein, play a pivotal role in proliferation, migration, differentiation and cell death. The cellular events *viz.* inflammation, infection and malignant conditions are observed due to binding of TNF- α binding to TNF- α receptors. Over-expression of TNF- α is responsible for the progression of pathological consequences *viz.* rheumatoid arthritis, ankylosing spondylitis, psoriasis and Crohn's disease²⁰. Thus, the drugs that act against TNF- α could be effective in the management of above mentioned inflammatory condition²¹. Many studies proved the inhibitory role of hesperidin in decreased expression of TNF- α . Hesperidin decreased TNF- α expression on vascular cell adhesion molecule-1 which further prevented association of monocytes to endothelium²². Similar effects were observed over other experimental models²³. The docking of hesperidin with TNF- α receptor represents a noteworthy interaction which

could be responsible for its inhibition (as observed from previous *in vitro* studies)¹³.

Various interactions with inflammatory and immune cells are arbitrated by a class of proteins termed as interleukins. Interleukins function to support 'cell growth, differentiation, and functional activation'.

IL-1 β and IL-6 are two important interleukins. They are produced by macrophages, T-cells and bone marrow stromal cells. IL-1 β (human leukocyte pyrogen/lymphocyte mitogen) is an important mediator to evoke an immune response. IL-1 β contributes towards the progression of pain, inflammation and cell apoptosis²⁴. Over-expression of IL-1 β is responsible for the progression of osteoarthritis, rheumatoid arthritis²⁵ and type 2 diabetes²⁶. Therefore, the blockade of IL-1 β and IL-1 receptors is an important strategy to suppress inflammation and associated inflammatory disorders. The binding site on A chain of IL-1 β receptor includes some residues *viz.* 11, 13-15, 20-22, 27, 29-36, 38, 126-131, 147, and 149²⁷. The binding energy of interaction between hesperidin and IL-1 β receptor as observed from docking study was -6.64. Hesperidin interacted with some residues of IL-1 receptor next to aforementioned active sites which include methionine 20, proline 23, glutamic acid 37. In many experiments, hesperidin has been studied for its possible inhibitory effect on IL-1 receptor and decreased expression of IL-1 β . In a study, hesperidin administration in rats (intoxicated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a hepatotoxin) caused a decrement in the levels of IL-1 β ²⁸. Many other studies also demonstrated

such effect²⁹. Thus, binding of hesperidin with some of the crucial residues on IL-1 β receptor may depict one of its effects as anti-inflammatory action.

IL-6 is another proinflammatory cytokine³⁰. IL-6 is secreted by macrophages and T-cells. It mediates the immune response after burns, trauma, and injury. Overproduction of IL-6 is associated with progression of rheumatoid arthritis³¹ and inflammatory bowel disease³². IL-6 is a hexameric structure with interlocking assembly³³. The site I interface of the structure is surrounded by phenylalanine residue. Arginine 179 and lysine 171, by virtue of hydrogen bond, confine the specificity. In the present study, the interaction of hesperidin with arginine 179 proves blockade activity on the IL-6 receptor and thus, down-regulation of IL-6 could be predisposed due to this interaction. This interaction may also unfold anti-inflammatory mechanism of hesperidin in many animal studies³⁴.

NOs is responsible for the production of nitric oxide from the substrate L-arginine³⁵. NOs bind calmodulin and contain haem. The activity of this enzyme increases in 'response' to lipopolysaccharide and cytokines. NOS finds an important role in numerous physiological and pathophysiological conditions, viz. regulation of blood pressure, infection, inflammation and progression of malignancies³⁶. The secretion of nitric oxide is increased in cytokine-activated macrophages³⁷. Nitric oxide, with respect to the immune system, regulates the growth, activity, and fatality of lymphocytes, macrophages, neutrophils, mast cells, antigen presenting cells, natural killer cells and antigen-presenting cells³⁸. Increased nitrite accumulation is observed during arthritis³⁹. Thus, a decrement in the activity of this enzyme may play a vital role in anticipating the inflammation. Some natural products have been tested for their potential NOS inhibitory activity. Extracts of *Acanthopanax senticosus*⁴⁰, *Feijoa sellowiana*⁴¹, and *Latycodon grandiflorum* significantly inhibited the activity of NOs⁴². Hesperidin was studied for inhibitory effect on lipopolysaccharide-induced over-expression of inducible nitric oxide synthase in mouse macrophage. Hesperidin in the test dose (10-30 μ M) caused a significant decrease in nitric oxide production. In present docking studies, the interaction of hesperidin with tyrosine 711 and glutamine 712 suggest its possible interaction with NOs. Altogether, hesperidin altogether with other flavonoids (rutin⁴³, catechin⁴⁴) showed immunomodulatory potential.

Conclusion

In the present study, we carried out docking studies on hesperidin on various inflammatory and immunomodulatory targets, with the purpose to study and analyse *in silico* interaction of former on later. The docking scores and analysis of the interactions of hesperidin suggest the ability of hesperidin to bind to multiple targets involved in inflammation and immunomodulation. Hesperidin interacted with various chemokines and inflammatory mediators' viz. TNF- α , IL-1 β , IL-6, and NOs. With each target, hesperidin demonstrated a noteworthy affinity for binding. Findings from the present study show that hesperidin may interact with several chemokines and inflammatory mediators. Further studies on hesperidin and associated flavonoids are necessary to develop and establish QSAR and QSPR studies that may serve a stepping stone for the development of novel, efficient and safe immune-modulator.

References

- 1 Parkin J & Cohen B, An overview of the immune system. *Lancet*, 357 (2001) 1777.
- 2 Iwasaki A & Medzhitov R, Control of adaptive immunity by the innate immune system. *Nat Immunol*, 16 (2015) 343.
- 3 Kidd BA, Wroblewska A & Boland MR, Mapping the effects of drugs on the immune system. *Nat Biotechnol*, 34 (2015) 47.
- 4 Sajid MS, Iqbal Z, Muhammad G & Iqbal MU, Immunomodulatory effect of various anti-parasitics: a review. *Parasitol*, 132 (2005) 301.
- 5 Souza MA, Carvalho FC, Ruas LP, Ricci-Azevedo R & Roque-Barreira MC, The immunomodulatory effect of plant lectins: A review with emphasis on Artin M properties. *Glycoconj J*, 30 (2013) 641.
- 6 Ganeshpurkar A & Saluja AK, Protective effect of rutin on humoral and cell mediated immunity in rat model. *Chem Biol Interact*, 273 (2017) 154.
- 7 Ganeshpurkar A & Saluja A, The Pharmacological Potential of Rutin. *Saudi Pharm J*, 25 (2017) 149.
- 8 Calderon M J, Burgos ME, Perez GC & Lopez LM, A Review on the Dietary Flavonoid Kaempferol. *Mini Rev Med Chem*, 11 (2011) 298.
- 9 Arriaga FJ & Rumbero A, Naringin, hesperidin and neohesperidin content in juices from thirteen Citrus ssp. *Essenze Deriv Agrum*, 61 (1990) 31.
- 10 Peterson JJ, Dwyer JT & Beecher GR, Flavanones in oranges, tangerines (mandarins), tangors, and tangelos: a compilation and review of the data from the analytical literature. *J Food Compos Anal*, 19 (2006) suppl. S66.
- 11 Lee YR, Jung JH & Kim HS, Hesperidin partially restores impaired immune and nutritional function in irradiated mice. *J Med Food*, 14 (2011) 475.
- 12 Camps M, Franch À, Pérez FJ & Castell M, Influence of hesperidin on the systemic and intestinal rat immune response. *Nutrients*, 9 (2017) 1.
- 13 Kawaguchi K, Kikuchi SI, Hasunuma R, Maruyama H, Yoshikawa T & Kumazawa Y, A citrus flavonoid hesperidin

- suppresses infection-induced endotoxin shock in mice. *Biol Pharm Bull*, 27 (2004) 679.
- 14 Yeh CC, Kao SJ, Lin CC, Wang S Der, Liu CJ & Kao ST, The immunomodulation of endotoxin-induced acute lung injury by hesperidin *in vivo* and *in vitro*. *Life Sci*, 80 (2007) 1821.
 - 15 Dourado GKZS, Ribeiro LCD, Carlos IZ & César TB, Orange juice and hesperidin promote differential innate immune response in macrophages *ex vivo*. *Int J Vitam Nutr Res*, 83 (2014):162.
 - 16 Python Software Foundation. Python Language Reference, version 2.7. Python Softw Found. 2013:Version 3.03., <http://www.python.org>.
 - 17 Forli W, Halliday S, Belew R & Olson A, AutoDock Version 4.2. Citeseer. 2012:1.
 - 18 Visualizer DS, v4. 0.100. 13345. Accelrys Softw Inc. 2005, 2013.
 - 19 Rizvi SMD, Shakil S & Haneef M, A simple click by click protocol to perform docking: Autodock 4.2 made easy for non-bioinformaticians. *Excli J*, 12 (2013) 830.
 - 20 Bradley JR, TNF-mediated inflammatory disease. *J Pathol*, 214 (2008) 149.
 - 21 Esposito E, Cuzzocrea S, TNF- α as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. *Curr Med Chem*, 16 (2009) 3152.
 - 22 Nizamutdinova IT, Jeong JJ & Xu GH, Hesperidin, hesperidin methyl chalone and phellopterin from *Poncirus trifoliata* (Rutaceae) differentially regulate the expression of adhesion molecules in tumor necrosis factor- α -stimulated human umbilical vein endothelial cells. *Int Immunopharmacol*, 8 (2008) 670.
 - 23 Jain M & Parmar HS, Evaluation of antioxidative and anti-inflammatory potential of hesperidin and naringin on the rat air pouch model of inflammation. *Inflamm Res*, 60 (2011) 483.
 - 24 Marchand F, Perretti M & McMahon SB, Role of the immune system in chronic pain. *Nat Rev Neurosci*, 6 (2005) 521.
 - 25 Schiff MH, Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. *Ann Rheum Dis*, 59 (2000) Suppl. 1 i103.
 - 26 Zhao G, Dharmadhikari G, Maedler K & Meyer HM, Possible role of interleukin-1 β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies. *PLoS Comput Biol*, 10 (2014) e1003798.
 - 27 Vigers GPA, Anderson LJ, Caffes P & Brandhuber BJ, Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 β . *Nature*, 386 (1997) 190.
 - 28 Bentli R, Ciftci O, Cetin A, Unlu M, Basak N & Çay M, Oral administration of hesperidin, a citrus flavonone, in rats counteracts the oxidative stress, the inflammatory cytokine production, and the hepatotoxicity induced by the ingestion of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). *Eur Cytokine Netw*, 24 (2013) 91.
 - 29 Li R, Cai L, Xie XF, Yang F & Li J, Hesperidin suppresses adjuvant arthritis in rats by inhibiting synoviocyte activity. *Phytother Res*, 24 (2010) Suppl. 1 S71.
 - 30 Ferguson C, Chen YF, Newman MS, May LT, Sehgal PB & Ruddle FH, Regional localization of the interferon- β 2/ β -cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. *Genomics*, 2 (1988) 203.
 - 31 Hirano T, Matsuda T & Turner M, Excessive production of interleukin 6/B cell stimulatory factor β 2 in rheumatoid arthritis. *Eur J Immunol*, 18 (1988) 1797.
 - 32 Mazlam MZ & Hodgson HJ, Interrelations between interleukin-6, interleukin-1 β , plasma C-reactive protein values, and *in vitro* C-reactive protein generation in patients with inflammatory bowel disease. *Gut*, 35 (1994) 77.
 - 33 Boulanger MJ, Chow D, Brevnova EE & Garcia KC, Hexameric structure and assembly of the interleukin-6/IL-6 α -receptor/gp130 complex. *Science*, 300 (2003) 2101.
 - 34 Parhiz H, Roohbakhsh A, Soltani F, Rezaee R & Iranshahi M, Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: An updated review of their molecular mechanisms and experimental models. *Phytother Res*, 29 (2015) 323.
 - 35 Wuebbles DJ, Nitrous Oxide: No Laughing Matter. *Science*, 326 (2009) 56.
 - 36 Lirk P, Hoffmann G & Rieder J, Inducible nitric oxide synthase--time for reappraisal. *Curr Drug Targets Inflamm Allergy*, 1 (2002) 89.
 - 37 Sharma JN, Alomran A & Parvathy SS, Role of nitric oxide in inflammatory diseases. *Inflammopharmacology*, 15 (2007) 252.
 - 38 Nussler AK & Billiar TR, Inflammation, immunoregulation, and inducible nitric oxide synthase. *J Leukoc Biol*, 54 (1993) 171.
 - 39 Bogdan C, Nitric oxide and the immune response. *Nat Immunol*, 2 (2001) 907.
 - 40 Lin QY, Jin LJ, Cao ZH & Xu YP, Inhibition of inducible nitric oxide synthase by *Acanthopanax senticosus* extract in RAW264.7 macrophages. *J Ethnopharmacol*, 118 (2008) 231.
 - 41 Rossi A, Rigano D & Pergola C, Inhibition of inducible nitric oxide synthase expression by an acetic extract from feijoa sellowiana Berg. fruits. *J Agric Food Chem*, 55 (2007) 5053.
 - 42 Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS & Kim YS, Inhibition of inducible nitric oxide synthase and cyclooxygenase II by *Platycodon grandiflorum* saponins via suppression of nuclear factor- κ B activation in RAW 264.7 cells. *Life Sci*, 76 (2005) 2315.
 - 43 Ganeshpurkar A & Saluja A, *In silico* interaction of rutin with some immunomodulatory targets: a docking analysis. *Indian J Biochem Biophys*, 55 (2018) 88.
 - 44 Ganeshpurkar A & Saluja A, *In silico* interaction of catechin with some immunomodulatory targets: A docking analysis. *Indian J Biotechnol*, 17 (2018) 626.